Background/Aims: The aim of this study is to explore the validity and reliability of the health-related quality of life SF-36 questionnaire in patients undergoing renal replacement therapy. Methods: A multicenter descriptive transversal study was carried out in Galicia, Spain, with patients undergoing renal replacement therapy. The tool used to measure the health-related quality of life was the authorized Spanish version of the ‘SF-36’ generic health questionnaire. The internal consistency of this survey was determined by means of interscale correlations and Cronbach’s α statistic. Validity was examined with a principal component exploratory factor analysis with Varimax rotation. Results: A total of 213 patients waiting for a kidney transplant and 72 recipients with a functioning renal transplant were studied. All the interscale correlations were positive and significant. The overall statistical value for Cronbach’s α was equal to 0.91 (95% CI: 0.91–0.94) and in all domains this value ranged from 0.7 to 0.92. The factor analysis identified 8 factors that explain 66.6% of the variance, 5 of which consisted of the same structure as 5 factors (domains) of the theoretical model. Conclusion: The SF-36 questionnaire is also a reliable and valid tool when used to measure the quality of life of patients undergoing renal replacement therapy.

1.
Comité de Registro de la SEN, Comunidades y Registros Autonómicos. Informe de diálisis y trasplante año 2001 de la Sociedad Española de Nefrología y Registros Autonómicos [cited 2003 Jun 4]: Available from: http://www.senefro.org/modules.php?name=subsection&idsection=7&idsubsection=128.
2.
Winkelmayer WC, Weinstein MC, Mittleman MA, Glynn RJ, Pliskin JS: Health economic evaluations: The special case of end-stage renal disease treatment. Med Decis Making 2002;22:417–430.
3.
Loubeau PR, Loubeau JM, Jantzen R: The economics of kidney transplantation versus hemodialysis. Prog Transplant 2001;11:291–297.
4.
Guyatt GH, Feeny D, Patrick D: Measuring health-related quality of life. Ann Intern Med 1993;118:622–629.
5.
Alonso J: La medida de la calidad de vida relacionada con la salud en la investigación y la práctica clínica. Gac Sanit 2000;14:163–167.
6.
Alonso J, Prieto L, Antó JM: La versión española del SF-36 Health Survey (Cuestionario de salud SF-36): Un instrumento para la medida de los resultados clínicos. Med Clin 1995;104:771–776.
7.
Rebollo P, Bobes J, González MP, Saiz P, Ortega F: Factores asociados a la calidad de vida relacionada con la salud (CVRS) de los pacientes en terapia renal sustitutiva (TRS). Nefrología 2000;20:171–181.
8.
Carmichael P, Popoola J, John I, Stevens PE, Carmichael AR: Assessment of quality of life in a single centre dialysis population using the KDQOL-SF questionnaire. Qual Life Res 2000;9:195–205.
9.
Merkus MP, Jager KJ, Dekker FW, de Haan RJ, Boeschoten EW, Krediet RT: Physical symptoms and quality of life in patients on chronic dialysis: Results of The Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD). Nephrol Dial Transplant 1999;14:1163–1170.
10.
Rebollo P, Ortega F, Baltar JM, Badia X, Alvarez-Ude F, Diaz-Corte C, Naves M, Navascues RA, Urena A, Alvarez-Grande J: Health related quality of life (HRQOL) of kidney transplanted patients: Variables that influence it. Clin Transplant 2000;14:199–207.
11.
Pinson CW, Feurer ID, Payne JL, Wise PE, Shockley S, Speroff T: Health-related quality of life after different types of solid organ transplantation. Ann Surg 2000;232:597–607.
12.
Fujisawa M, Ichikawa Y, Yoshiya K, Isotani S, Higuchi A, Nagano S, Arakawa S,Hamami G, Matsumoto O, Kamidono S: Assessment of health-related quality of life in renal transplant and haemodialysis patients using the SF-36 health survey. Urology 2000;56:201–206.
13.
Merkus MP, Jager KJ, Dekker FW, De Haan RJ, Boeschoten EW, Krediet RT: Quality of life over time in dialysis: The Netherlands Cooperative Study on the Adequacy of Dialysis. NECOSAD Study Group. Kidney Int 1999;56:720–728.
14.
Korevaar JC, Jansen MA, Merkus MP, Dekker FW, Boeschoten EW, Krediet RT: Quality of life in predialysis end-stage renal disease patients at the initiation of dialysis therapy. The NECOSAD Study Group. Perit Dial Int 2000;20:69–75.
15.
Rebollo P, Ortega F, Badía X, Alvarez-Ude F, Baltar J, Valdés F, et al: Salud percibida en pacientes mayores de 65 años en tratamiento sustitutivo renal (TSR). Nefrología 1999;19(suppl 1):73–83.
16.
Hays RD, Anderson R, Revicki D: Psychometric considerations in evaluating health-related quality of life measures. Quality Life Res 2–1993.
17.
Cella DF, Dineen K, Arnason B, Reder A, Webster KA, Karabatsos G, Chang C, Lloyd S, Steward J, Stefoski D: Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996;47:129–139.
18.
Fitzpatrick R, Fletcher A, Gore S, Jones D, Spiegelhalter D, Cox D: Quality of life measures in health care. I. Applications and issues in assessment. BMJ 1992;305:1074–1077.
19.
Fletcher A, Gore S, Jones D, Fitzpatrick R, Spiegelhalter D, Cox D: Quality of life measures in health care. II. Design, analysis, and interpretation. BMJ 1992;305:1145–1148.
20.
Batista-Foguet JM, Coenders G, Alonso J: Confirmatory factor analysis. Its role on the validation of health related questionnaires. Med Clin (Barc) 2004;122(suppl 1):21–27.
21.
Testa M, Nackley JF: Methods for quality of life studies. Annu Rev Public Health 1994;15:535–559.
22.
Sánchez Carrión JJ (ed): Introducción a las técnicas de análisis multivariable aplicadas a las ciencias sociales. Madrid, Centro de Investigaciones Sociológicas, 1984.
23.
Comrey AL: Manual de Análisis Factorial. Madrid, Cátedra, 1985.
24.
Calidad de vida y ensayos clínicos (editorial]). Lancet (ed Esp) 1995;346(separata especial): 1–2.
25.
Gill TM, Feinstein AR: A critical appraisal of the quality of quality of life measurements. JAMA 1994;272:619–626.
26.
Neto JF, Ferraz MB, Cendoroglo M, Draibe S, Yu L, Sesso R: Quality of life at the initiation of maintenance dialysis treatment a comparison between the SF-36 and the KDQ questionnaires. Qual Life Res 2000;9:101–107.
27.
Merkus MP, Jager KJ, Dekker FW, Boeschoten EW, Stevens P, Krediet RT: Quality of life in patients on chronic dialysis: Self-assessment 3 months after the start of treatment. The Necosad Study Group. Am J Kidney Dis 1997;29:584–592.
28.
Alonso J, Regidor, Barrio G, Prieto L, Rodríguez C, Fuente de la L: Valores poblacionales de referencia de la versión española del Cuestionario de Salud SF-36. Med Clin 1998;111:410–416.
29.
Bremer BA, Wert KM, Durica AL, Weaver A: Neuropsychological, physical, and psychosocial functioning of individuals with end-stage renal disease. Ann Behav Med 1998;19:348–352.
30.
Mingardi G, Cornalba L, Cortinovis E, Ruggiata R, Mosconi P, Apolone G: Health-related quality of life in dialysis patients: A report from an Italian study using the SF-36 Health Survey. DIA-QOL Group. Nephrol Dial Transplant 1999;14:1503–1510.
31.
Zúniga MA, Carrillo-Jiménez GT, Fos PJ, Gandek B, Medina-Moreno MR: Evaluación del estado de salud con la Encuesta SF-36:resultados preliminares en México. Salud Pública Mex 1999;41:110–118.
32.
Ozminkowski RJ, White AJ, Hassol A, Murphy M: General health of end stage renal disease program beneficiaries. Health Care Financ Rev 1997;19:121–144.
33.
Failde I, Ramos I: Validity and reliability of the SF-36 Health Survey Questionnaire in patients with coronary artery disease. J Clin Epidemiol 2000;53:359–365.
34.
Ayuso-Mateos JL, Lasa L, Vazquez-Barquero JL, Oviedo A, Diez Manrique JF: Measuring health status in psychiatric community surveys: Internal and external validity of the Spanish version of the SF-36. Acta Psychiatr Scand 1999;99:26–32.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.